This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT05929079 |
|---|---|
| Status | Completed |
| Phase | Phase 3 |
| Sponsor | Eli Lilly and Company |
| Enrollment | 1,152 participants |
| Design | Interventional, Randomized, Parallel, Masking: Double |
| Conditions | Type 2 Diabetes; Obesity; Overweight; Obstructive Sleep Apnea |
| Interventions | Retatrutide; Placebo |
| Start | Jul 11, 2023 |
| Primary completion | Jun 16, 2026 |
| Study completion | Jun 16, 2026 |
| Results posted | Not yet |
| Registry last updated | Jul 30, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study will last about 89 weeks and will include up to 24 visits.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Percent Change from Baseline in Body Weight | Baseline, Week 80 |
| Change from Baseline in Apnea-Hypopnea Index (AHI) for GSA2 Subset | Baseline, Week 80 |
14 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 17, 2026. See the trial changes feed for what has changed recently.
More trials of Retatrutide
- TRIUMPH-1: Retatrutide, Phase 3 (NCT05929066)
- Retatrutide: Phase 2 Trial (NCT05936151)
- Retatrutide: Phase 3 Trial in Obesity (NCT07357415)
- TRANSCEND-T2D-1: Retatrutide, Phase 3 (NCT06354660)
- TRANSCEND-T2D-2 Trial (NCT06260722): Retatrutide and Semaglutide
- Retatrutide: Phase 3 Trial in Obesity (NCT05931367)
Research area: Metabolic and incretin. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.